MatriDerm FDA Clearance
In January 2021 the FDA cleared our dermal matrix MatriDerm® for use in the management of full thickness and partial thickness wounds.
MatriDerm® is our single use three-dimensional acellular dermal matrix that is comprised of our native bovine collagen and bovine elastin. The technology is supported by over 150 peer reviewed published articles and currently sold across the world having treated over 300,000 patients.
We are absolutely delighted at MedSkin Solutions Dr. Suwelack that we can begin to commercialize MatriDerm® in the USA – bringing our clinically proven technology to a wider audience of Healthcare Professionals to support their care regime.
Our CEO, Diana Ferro, said "We are pleased with receiving 510(k) clearance for our unique MatriDerm® products. This significant milestone represents our commitment at MedSkin Solutions Dr. Suwelack in bringing innovation and differentiated technologies to healthcare professionals and patients around the world”. Jason Gugliuzza, our Vice President MedCare Division, followed "Like we have done across Europe, the Middle East, Asia, and Latin America our focus will be educating and supporting healthcare professionals and our partners as we look to commercialize MatriDerm® in the largest medical device market globally,"
Congratulations to our whole MatriDerm team on this milestone for our portfolio!